Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $468000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 35.65% year-over-year to $468000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 6.54% YoY), and the FY2025 full-year result was $1.6 million, down 8.32% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $468000.0, roughly flat from $467000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $656000.0 in Q1 2022, with the low at $345000.0 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $497647.1 across 5 years, with a median of $468000.0 in 2026.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 110.26% — and 2024, when it slumped 33.83%.
• Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) stood at $602000.0 in 2022, then dropped by 10.3% to $540000.0 in 2023, then declined by 25.93% to $400000.0 in 2024, then gained by 16.75% to $467000.0 in 2025, then increased by 0.21% to $468000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $468000.0 (Q1 2026), $467000.0 (Q4 2025), and $384000.0 (Q3 2025), per Business Quant data.